Viking Therapeutics, Inc.
NASDAQViking Therapeutics enters the post-earnings stretch with its heaviest short position in months still intact — even as the stock slipped further following a wider-than-expected Q1 loss. Short sellers have not blinked. At 20.1% of free float, the ORTEX short interest estimate is the dominant feature of Viking's positioning right now. The figure has actually eased modestly from its…
Snapshot as of 8 May 2026
Viking Therapeutics enters the post-earnings stretch with its heaviest short position in months still intact — even as the stock slipped further following a wider-than-expected Q1 loss. Short sellers have not blinked.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VKTX — free to start on ORTEX.
Sign up for free →Open VKTX on ORTEX